Pharmaceuticals Sector - Solvay

More documents

Recommendations

Info

SOLVAY An international Chemicals and Pharmaceuticals group Facts and fi gures: Sales: 8.6 GEUR Cash fl ow: 1.3 GEUR Employing 28 730 people Present in 50 countries on every continent With 400 centres Over 95% of sales come from outside Belgium and 49% from outside the European Union Stable or rising dividends every year for 24 years Operates in three sectors: Pharmaceuticals, Chemicals and Plastics Group Activities Reponsibilities Management Report and Financial Statements Contents 02 01 Highlights 02 Strategy, Mission, Vision, Values 04 Chairmen’s Message 06 Board of Directors and Corporate Governance 08 08 Executive Committee and General Managers 10 Christian Jourquin’s Message 12 Our Positions 14 Pharmaceuticals Sector 24 Chemicals Sector 32 Plastics Sector 40 New Business Development 44 44 Human Resources 48 Sustainable Development 52 52 Table of contents 53 Management Report 57 Financial Statements 105 Auditor’s Report on the Consolidated Financial Statements 106 Information for shareholders
Highlights January 2005 Solvay fi nalizes the sale to BP of its interests in the BP Solvay Polyethylene joint ventures, concluding a series of transactions initiated by Solvay and BP in 2000. April 2005 Solvay Solexis begins marketing its new grade of TECNOFLON ® perfl uorinated elastomers, created by a brand-new polymerization technology able to generate products with unequalled properties. October 2005 Solvay Pharma launches its project to integrate Fournier Pharma and create the future « Solvay Pharmaceuticals ». February 2005 The Rigid Plastic Foils activity, comprising the two Italian plants at Monfalcone and Fucine, is sold to Ineos. Vinythaï decides to integrate upstream in the PVM and VCM (vinyl chloride monomer) chain by doubling chlorine and ethylene dichloride production capacity at its Map Ta Phut plant (Thailand). July 2005 Solvay agrees to sell its entire Industrial Foils activities – development, production and marketing of plastic fi lms and foils – to Renolit AG (Germany). Solvay concludes its major stategic acquisition of 100% of Fournier Pharma. November 2005 Solvay and Chemical Products Corporation (CPC) of the USA create a joint venture for their technical-grade barium and strontium carbonate activities. March 2005 Solvay and Fournier Pharma’s shareholders sign agreement for Solvay’s acquisition of 100% of Fournier Pharma. May 2005 Solvay Solexis announces two major capacity expansions for ALGOFLON ® and HYFLON ® fl uorinated polymers at Spinetta Marengo (Italy). Solvay announces creation of a joint venture in China to produce ultra-pure hydrogen peroxide. August 2005 Solvay Organics GmbH successfully concludes its public offer for chemical specialties company Girindus AG, operating out of Bensberg, Germany, with a site at Cincinnati, Ohio (USA), and creates a new “Molecular Solutions” Strategic Business Unit. 2005 Highlights June 2005 Solvay announces plant at Onsan (South Korea) to produce inorganic fl uorinated specialties for high-growth markets. September 2005 Solvay creates a Technical Centre at Shanghai, China, in response to growing demand from Chinese customers for Specialty Polymers (Solvay High Performance Materials R&D (Shanghai) Co., Ltd). December 2005 Solvay and Gharda (India) sign an agreement for Solvay to acquire Gharda’s plastics division, providing access to very high performance PEEK polymers and additional polysulfone capacity. Solvay signs partnership agreement with BASF and Dow for production of hydrogen peroxide to supply propylene oxide production at Antwerp (Belgium). Solvay Global Annual Report 2005 3
Page 1: Driven by the future Growth, Compet
Page 5 and 6: Activities Group sales 2005 = EUR 8
Page 7 and 8: Our Vision - Independent industrial
Page 9 and 10: here to stay, in our view irreversi
Page 11 and 12: Board of Directors and Corporate Go
Page 13 and 14: 4 Executive Committee and General M
Page 15 and 16: Such a strategy is possible only wi
Page 17 and 18: Specialities Solvay Specialties fro
Page 19 and 20: Key fi gures [EUR million] Pharmace
Page 21 and 22: Cardiometabolic Cardiovascular dise
Page 23 and 24: Cardiometabolics Fenofi brate, TRIC
Page 25 and 26: “ DUODOPA® entered Solvay’s pr
Page 27 and 28: Pharmaceuticals Sector Therapeutic
Page 29 and 30: Key fi gures [EUR million] Chemical
Page 31 and 32: Growth To speed up its growth, the
Page 33 and 34: Initiatives have also been launched
Page 35 and 36: “ The ‘Soil Remediation Reagent
Page 37 and 38: Key fi gures [EUR million] Plastics
Page 39 and 40: Innovation “Twin-Sheet Blow Mould
Page 41 and 42: Plastics 37 Solvay Global Annual Re
Page 43 and 44: which it was able to take advantage
Page 45 and 46: New Business Development Priority t
Page 47 and 48: Meeting The Science Days organized
Page 49 and 50: Human Resources The Group’s fi ve
Page 51 and 52: “ At the end of this seminar, all
Page 53 and 54:
Sustainable Development 2005 saw th
Page 55 and 56:
Accident frequency rate Persons wor
Page 57 and 58:
Management Report New records for S
Page 59 and 60:
Expenditure on the future by Sector
Page 61 and 62:
Financial Statements The following
Page 63 and 64:
Consolidated balance sheet EUR mill
Page 65 and 66:
IFRS valuation rules The main accou
Page 67 and 68:
9. Impairment Every year the Group
Page 69 and 70:
Notes to the fi nancial statements
Page 71 and 72:
(2) Financial data by region These
Page 73 and 74:
and the estimated fi nancial conseq
Page 75 and 76:
The deferred taxes recorded in the
Page 77 and 78:
2005 Millions EUR Acquisitions Disp
Page 79 and 80:
Neopharma On January 19, 2005 the S
Page 81 and 82:
(around 300 persons) with a view to
Page 83 and 84:
In 2005 the impairment tests on goo
Page 85 and 86:
Solvay Group purchased 100% of the
Page 87 and 88:
Post-employment benefi t plans are
Page 89 and 90:
Actuarial assumptions used in deter
Page 91 and 92:
Analysis of total fi nancial debt b
Page 93 and 94:
In this way, at the end of 2005, th
Page 95 and 96:
The following amounts relating to J
Page 97 and 98:
PORTUGAL Fournier Farmaceutica Port
Page 99 and 100:
List of fully consolidated Group co
Page 101 and 102:
Solvay Salz Holding GmbH, Hannover
Page 103 and 104:
CANADA Fournier Pharma, Inc., Montr
Page 105 and 106:
GREAT BRITAIN Inergy Automotive Sys
Page 107 and 108:
Summary fi nancial statements of So
Page 109 and 110:
Statutory auditor’s report to the
Page 111 and 112:
The Solvay share compared with the
Page 113 and 114:
Contacts: The Investor Relations Te
Page 115 and 116:
Shareholders’ Diary - May 9, 2006
show all

Pharmaceuticals Sector - Solvay

Create successful ePaper yourself

Delete template?

Save as template?